APOA1 Protein (AA 19-267)

Catalog No. ABIN7318169

This Recombinant APOA1 protein is expressed in Escherichia coli (E. coli).

Quick Overview for APOA1 Protein (AA 19-267) (ABIN7318169)

Target: APOA1 (Apolipoprotein A-I (APOA1))

Protein Type: Recombinant

Origin: Human

Source: Escherichia coli (E. coli)

Purity: > 95 % as determined by reducing SDS-PAGE.

Product Details

Protein Characteristics: AA 19-267

Purpose: Recombinant Human Apolipoprotein A-I/ApoAI Protein

Sequence: Arg19-Gln267

Characteristics: Recombinant Human Apolipoprotein A-I is produced by our E.coli expression system and the target gene encoding Arg19-Gln267 is expressed.

Sterility: 0.2 μm filtered

Endotoxin Level: < 1.0 EU per μg of the protein as determined by the LAL method.

Biological Activity Comment: Not validated for activity

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: Lyophilized from a 0.2 μm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.2.
Normally 5 % - 8 % trehalose, mannitol and 0.01 % Tween 80 are added as protectants before lyophilization.

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Expiry Date: 12 months

Target Details

Target: APOA1 (Apolipoprotein A-I (APOA1))

Alternative Name: Apolipoprotein A-I

Background: APOA1,Apo-AI,ApoA-I,Apolipoprotein A-I,Apolipoprotein A1,Apolipoprotein A1 (APOA1) is a secreted protein which belongs to the Apolipoprotein A1/A4/E family. APOA1 is the major protein component of high density lipoprotein (HDL) in plasma. APOA1 plays a critical role in various biological processes, such as Cholesterol metabolism, Lipid metabolism and transport, Steroid metabolism. APOA1 promotes cholesterol efflux from tissues to the liver and thus helps to clear cholesterol from arteries. Defects in this gene resulted in HDL deficiencies, including Tangier disease (TGD), systemic non-neuropathic amyloidosis, premature coronary artery disease, hepatosplenomegaly and progressive muscle wasting and weakness. In addition, ApoA-I is implicated in the anti-endotoxin function of HDL via interaction with lipopolysaccharide or endotoxin.

Molecular Weight:

Calculated MW: 29.0 kDa

Observed MW: 25-31 kDa

Gene ID: 335

UniProt: P02647

Pathways: Regulation of Lipid Metabolism by PPARalpha, Production of Molecular Mediator of Immune Response, Lipid Metabolism